vimarsana.com

Latest Breaking News On - Ibrahim aldoss - Page 4 : vimarsana.com

Revumenib trial meets complete remission endpoint for acute leukemia subsets

Revumenib trial meets complete remission endpoint for acute leukemia subsets
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Ibrahim aldossSyndax pharmaceuticals

Syndax announces positive results for leukemia therapy ruvumenib

Syndax Pharmaceuticals says it is ‘thrilled’ to report positive top line results for its treatment for acute leukemia.

Michael metzgerIbrahim aldossDrug administrationData monitoring committeeTherapy designationIndependent data monitoring committeeClinical developmentDrug deliveryPis active pharmaceutical ingredientsPhase iii ivClinical trials

Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis

– Trial met its primary endpoint with a CR/CRh rate of 23% at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); an additional 14%.

Michaela metzgerIbrahim aldossSharon klahreDepartment of hematology hematopoietic cell transplantationPharmaceuticals incEuropean commissionData monitoring committeeDivision of leukemiaExchange commissionSyndax pharmaceuticalsSyndax pharmaceuticals incDrug administrationPrnewswire syndax pharmaceuticals nasdaqInternational numberIndependent data monitoring committeeChief executive officer

Syndax s acute leukemia drug succeeds in pivotal study

Syndax’s drug, which is being tested for an aggressive form of leukemia, was stopped early for efficacy.

Ibrahim aldossMichael metzgerDrug administrationSyndax pharmaceuticalsBreakthrough therapy designation

Revumenib Meets CR/CRh End Point in KMT2A-Rearranged Relapsed/Refractory AML/ALL

Treatment with the first-in-class menin inhibitor revumenib generated complete remissions or complete remissions with partial hematological recovery in adult and pediatric patients with relapsed/refractory acute myeloid leukemia or acute lymphoblastic leukemia harboring KMT2A rearrangements.

Karnofsky lanskyIbrahim aldossMichaela metzgerSyndax pharmaceuticalsHematopoietic cell transplantationPatients with relapsed refractory acute myeloid leukemiaAcute lymphoblastic leukemiaAugment 101 trialCity of hope

vimarsana © 2020. All Rights Reserved.